Skip to main content

Lsl Pharma Group Inc(LSL-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.385
Day High0.405
Open:0.405
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Lsl Pharma Group Inc

Select a category then submit the form to load news
Newswire.ca
LSL PHARMA GROUP GRANTS STOCK OPTIONS
Newswire.ca
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
Newswire.ca
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
Newswire.ca
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
Newswire.ca
LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
Newswire.ca
LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS
Newswire.ca
LSL PHARMA GROUP COMPLETES THE ACQUISITION OF LABORATOIRE DU-VAR INC.
Newswire.ca
HEALTH CANADA GRANTS LSL PHARMA GROUP APPROVAL TO COMMERCIALIZE SIX NEW STERILE OPHTHALMIC SOLUTIONS
Newswire.ca
LSL PHARMA GROUP ANNOUNCES APPOINTMENTS TO ITS BOARD OF DIRECTORS
Newswire.ca
LSL PHARMA GROUP CLOSES A $2.275M NON-BROKERED PRIVATE PLACEMENT
Newswire.ca
LSL PHARMA GROUP REPORTS THIRD CONSECUTIVE RECORD QUARTERLY REVENUES AND Q2 2025 FINANCIAL RESULTS
Newswire.ca
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES
Newswire.ca
LSL PHARMA GROUP ENTERS INTO NON-BINDING AGREEMENT TO ACQUIRE A QUEBEC-BASED COMPETITOR
AI-generated - The Globe and Mail
LSL Pharma Group: Top 10 Undervalued Drug Manufacturers Industry Stocks (LSL)
Newswire.ca
LSL PHARMA GROUP ANNOUNCES REDEMPTION OF 11% UNSECURED CONVERTIBLE DEBENTURES
Newswire.ca
LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Newswire.ca
LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC
AI-generated - The Globe and Mail
LSL Pharma Group: Top 10 Undervalued Drug Manufacturers Industry Stocks (LSL)
Newswire.ca
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2025 RESULTS
AI-generated - The Globe and Mail
LSL Pharma Group: Top 10 Undervalued Drug Manufacturers Industry Stocks (LSL)
Newswire.ca
LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2024 RESULTS
PR Newswire
LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"
Newswire.ca
LSL PHARMA GROUP ANNOUNCES THE SEMI-ANNUAL INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB
Newswire.ca
LSL PHARMA GROUP ANNOUNCES THE SIGNING OF TWO AGREEMENTS TO MARKET NEW OPHTHALMIC PRODUCTS IN CANADA
Newswire.ca
LSL PHARMA GROUP APPOINTS LOUIS LAFLAMME TO THE BOARD OF DIRECTORS
PR Newswire
LSL PHARMA GROUP GRANTS SHARE OPTIONS
Newswire.ca
LSL PHARMA GROUP SECURES A NEW $5.0 MILLION TERM LOAN
PR Newswire
LSL PHARMA GROUP EXPANDS ITS ACTIVITIES BY AQUIRING DERMOLAB PHARMA AND ANNOUNCES THE CLOSING OF A CONCURRENT DEBT FINANCING
PR Newswire
LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES
Newswire.ca
LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP
PR Newswire
LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP
Newswire.ca
LSL PHARMA GROUP ANNOUNCES THE FIRST INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

Profile

LSL Pharma Group Inc integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.